Monte Rosa Therapeutics, Inc. (GLUE) Net Income by Year
Monte Rosa Therapeutics, Inc. reported a net loss of $38.6M in fiscal year 2025. This represents an increase of 46.9% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a $161.1M net loss. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Monte Rosa Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
GLUE Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
GLUE Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Monte Rosa Therapeutics, Inc. financials
Frequently Asked Questions
What was Monte Rosa Therapeutics, Inc.'s net income in fiscal year 2025?
Monte Rosa Therapeutics, Inc. reported a net loss of $38.6M in fiscal year 2025.
How fast is Monte Rosa Therapeutics, Inc.'s net income growing?
Monte Rosa Therapeutics, Inc. (GLUE) net income rose by 46.9% year over year, from -$72.7M to -$38.6M in fiscal year 2025.
What is Monte Rosa Therapeutics, Inc.'s net income over the last twelve months?
Monte Rosa Therapeutics, Inc. (GLUE) reported a $161.1M net loss over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has Monte Rosa Therapeutics, Inc.'s net income changed over the years?
Across the 6 fiscal years this page covers, Monte Rosa Therapeutics, Inc. (GLUE) net income went from -$35.9M in fiscal year 2020 to -$38.6M in fiscal year 2025.
What was Monte Rosa Therapeutics, Inc.'s net income in the most recent quarter?
Monte Rosa Therapeutics, Inc. (GLUE) reported -$43.4M in net income in Q2 2026. This represents a decrease of 253.0% from the same quarter a year earlier.
What does net income mean on a financial statement?
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Monte Rosa Therapeutics, Inc. (GLUE) reported on that line in every period on record.